Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. TME Pharma N.V.
  6. News
  7. Summary
    ALTME   NL0015000YE1

TME PHARMA N.V.

(ALTME)
  Report
Real-time Euronext Paris  -  11:21:10 2023-01-27 am EST
1.150 EUR   -3.97%
01/23Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Combination with Radiotherapy and Bevacizumab in Patients with Glioblastoma
CI
01/20Tme Pharma N : Half-yearly report on the liquidity contract with Invest Securities
PU
2022Tme Pharma N : announces convocation of an extraordinary general meeting of shareholders
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

TME Pharma N.V. Announces the Resignation of Bryan Jennings as Chief Financial Officer

11/28/2022 | 12:00pm EST
share with twitter
share with LinkedIn
share with facebook

TME Pharma N.V. announced that the company's Chief Financial Officer (CFO), Bryan Jennings, has resigned for personal reasons. He will remain in his role through December 31, 2022, in order to ensure a smooth transition period.


© S&P Capital IQ 2022
All news about TME PHARMA N.V.
01/23Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Comb..
CI
01/20Tme Pharma N : Half-yearly report on the liquidity contract with Invest Securities
PU
2022Tme Pharma N : announces convocation of an extraordinary general meeting of shareholders
PU
2022Biotech Group TMA Pharma's CFO to Leave by 2022-end
MT
2022Tme Pharma N : announces the resignation of its Chief Financial Officer Bryan Jennings
PU
2022TME Pharma N.V. Announces Executive Changes
CI
2022TME Pharma N.V. Announces the Resignation of Bryan Jennings as Chief Financial Officer
CI
2022Tme Pharma N : The presentation
PU
2022TME Pharma N.V. - POSITIVE UPDATED INTERIM RESULTS FROM NOX-A12 GLORIA PHASE 1/2 IN BRA..
AQ
2022TME Pharma Announces Positive Updated Interim Results from NOX-A12 GLORIA Phase 1/2 in ..
CI
More news
Financials
Sales 2021 0,03 M 0,04 M 0,04 M
Net income 2021 -14,5 M -15,7 M -15,7 M
Net cash 2021 7,02 M 7,62 M 7,62 M
P/E ratio 2021 -1,07x
Yield 2021 -
Capitalization 1,56 M 1,70 M 1,70 M
EV / Sales 2020 405x
EV / Sales 2021 316x
Nbr of Employees 13
Free-Float 12,3%
Chart TME PHARMA N.V.
Duration : Period :
TME Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TME PHARMA N.V.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Aram Andrew Mangasarian Chief Business Officer
Maurizio PetitBon Chairman-Supervisory Board
Cornelis Alexander Izeboud Member-Supervisory Board
Martine J. van Vugt Member-Supervisory Board
Susan Coles Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
TME PHARMA N.V.-1.50%2
MODERNA, INC.7.49%74 239
LONZA GROUP AG17.19%42 748
IQVIA HOLDINGS INC.11.53%42 445
ALNYLAM PHARMACEUTICALS, INC.-3.63%28 492
SEAGEN INC.8.70%25 936